Glaukos Corporation (GKOS): Price and Financial Metrics
GET POWR RATINGS... FREE!
GKOS POWR Grades
- Quality is the dimension where GKOS ranks best; there it ranks ahead of 56.94% of US stocks.
- GKOS's strongest trending metric is Quality; it's been moving down over the last 177 days.
- GKOS ranks lowest in Sentiment; there it ranks in the 9th percentile.
GKOS Stock Summary
- GKOS's price/sales ratio is 8.79; that's higher than the P/S ratio of 85.9% of US stocks.
- In terms of twelve month growth in earnings before interest and taxes, GLAUKOS CORP is reporting a growth rate of 198.94%; that's higher than 92.19% of US stocks.
- As for revenue growth, note that GKOS's revenue has grown -3.1% over the past 12 months; that beats the revenue growth of just 20.44% of US companies in our set.
- Stocks that are quantitatively similar to GKOS, based on their financial statements, market capitalization, and price volatility, are AAOI, EYPT, ONDS, MRIN, and TTNP.
- Visit GKOS's SEC page to see the company's official filings. To visit the company's web site, go to www.glaukos.com.
GKOS Valuation Summary
- In comparison to the median Healthcare stock, GKOS's price/sales ratio is 285.71% higher, now standing at 8.1.
- Over the past 93 months, GKOS's EV/EBIT ratio has gone up 90.2.
Below are key valuation metrics over time for GKOS.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
GKOS | 2023-01-30 | 8.1 | 4.2 | -25.7 | -34.0 |
GKOS | 2023-01-27 | 8.0 | 4.2 | -25.6 | -33.8 |
GKOS | 2023-01-26 | 8.1 | 4.2 | -25.6 | -33.9 |
GKOS | 2023-01-25 | 8.0 | 4.2 | -25.5 | -33.7 |
GKOS | 2023-01-24 | 8.1 | 4.2 | -25.6 | -33.9 |
GKOS | 2023-01-23 | 8.2 | 4.3 | -26.2 | -34.5 |
GKOS Growth Metrics
- The 3 year revenue growth rate now stands at 50.5%.
- Its 5 year revenue growth rate is now at 87.32%.
- The 3 year net income to common stockholders growth rate now stands at -139.57%.

The table below shows GKOS's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 284.875 | -33.598 | -89.607 |
2022-06-30 | 288.316 | 10.707 | -55.801 |
2022-03-31 | 293.724 | 30.304 | -27.747 |
2021-12-31 | 294.011 | 24.708 | -49.593 |
2021-09-30 | 294.005 | 39.963 | -38.369 |
2021-06-30 | 284.126 | 12.603 | -60.347 |
GKOS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- GKOS has a Quality Grade of C, ranking ahead of 54.76% of graded US stocks.
- GKOS's asset turnover comes in at 0.279 -- ranking 135th of 186 Medical Equipment stocks.
- FONR, ATRC, and BSX are the stocks whose asset turnover ratios are most correlated with GKOS.
The table below shows GKOS's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.279 | 0.747 | -0.076 |
2021-03-31 | 0.236 | 0.681 | -0.129 |
2020-12-31 | 0.238 | 0.592 | -0.218 |
2020-09-30 | 0.243 | 0.595 | -0.310 |
2020-06-30 | 0.291 | 0.632 | -0.400 |
2020-03-31 | 0.432 | 0.731 | -0.328 |
GKOS Stock Price Chart Interactive Chart >
GKOS Price/Volume Stats
Current price | $51.52 | 52-week high | $64.49 |
Prev. close | $52.48 | 52-week low | $33.33 |
Day low | $51.52 | Volume | 419,900 |
Day high | $53.32 | Avg. volume | 389,061 |
50-day MA | $46.10 | Dividend yield | N/A |
200-day MA | $48.58 | Market Cap | 2.46B |
Glaukos Corporation (GKOS) Company Bio
Glaukos Corporation develops and commercializes products and procedures designed for the treatment of glaucoma. The company was founded in 1998 and is based in Laguna Hills, California.
Latest GKOS News From Around the Web
Below are the latest news stories about GLAUKOS CORP that investors may wish to consider to help them evaluate GKOS as an investment opportunity.
Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22ALISO VIEJO, Calif., February 01, 2023--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2022 financial results after the market close on Wednesday, February 22, 2023. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February |
15 Largest Ophthalmology Companies in the WorldIn this article, we will take a look at the 15 largest ophthalmology companies in the world. If you want to see more companies in this selection, go to the 5 Largest Ophthalmology Companies in the World. The ophthalmology industry encompasses the diagnosis, treatment, and prevention of eye disorders and diseases. This includes medical and […] |
Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline ProgramsALISO VIEJO, Calif., January 10, 2023--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced positive clinical updates for several of its Corneal Health pipeline programs, including the commencement of subject enrollment in a second Phase 3 confirmatory trial for Epioxa™ (Epi-on™), and promising initial results from the company’s Phase 2a clini |
Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and TolerabilityALISO VIEJO, Calif., January 10, 2023--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced positive results for a prospective, multi-center clinical trial designed to evaluate the safety of the surgical exchange procedure for iDose® TR (travoprost intraocular implant) in subjects who had previously been administered an iDose TR in the Phase 2 |
Here's Why You Should Retain Glaukos (GKOS) in Your PortfolioGlaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results. |
GKOS Price Returns
1-mo | 14.06% |
3-mo | 5.53% |
6-mo | 2.28% |
1-year | -4.84% |
3-year | -18.93% |
5-year | 76.08% |
YTD | 17.95% |
2022 | -1.71% |
2021 | -40.95% |
2020 | 38.17% |
2019 | -3.03% |
2018 | 118.99% |
Continue Researching GKOS
Want to do more research on GLAUKOS Corp's stock and its price? Try the links below:GLAUKOS Corp (GKOS) Stock Price | Nasdaq
GLAUKOS Corp (GKOS) Stock Quote, History and News - Yahoo Finance
GLAUKOS Corp (GKOS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...